R&D-based & market-focused pharmaceutical company
Highly efficient R&D team and superior products with worldwide IP protection Targeting 3.5 years from discovery to IND Experienced in filling First Class New Drug IND & NDA in China Striving for fast market entry and price protection
![](/uploads/files/page/business-flow-en.svg)
Multiple Business Model
With multiple and flexible business model system adapting to different market needs and regulations.
![](/uploads/files/page/business-pic01.svg)
Joint venture
(HEC model)
![](/uploads/files/page/business-pic02a.svg)
Local manufacturing & marketing
(ZheJiang Medicine model)
![](/uploads/files/page/business-pic03.svg)
Drug product supply
(Carnot)
Nemonoxacin out-licensing to 36 countries worldwide
Antibiotic resistance is one of the threats in public health. New generation antibiotic will satisfy the unmet medical needs. Non-fluorinated quinolone, nemonoxacin, has been out-licensed to Asia, East Europe and Central, South America, Canada, New Zealand, Australia and South Korea.
![](/uploads/files/page/business-map.svg)
- Russian market
- R-Pharm
- Russia, Turkey and Commonwealth Independent States
- Latin America
- Carnot (Productos Científicos)
- Mexico, Brazil and Latin American Market
- CA, NZ & AU market
- Luminarie Canada
- Canada, New Zealand & Australia
- China market
- Zhejiang Medicine
- Mainland China
- South Korea market
- GPCR Therapeutics
- South Korea
- Taiwan market
- Holding Disp
- Taiwan